An investigational single-molecule agonist of both the GLP-1 and amylin receptors, developed by Novo Nordisk in injectable and oral forms. Two phase 1 human trials were published in The Lancet in 2025, and phase 3 trials were planned to start in 2026.
Amycretin is a single long-acting molecule designed to activate both the GLP-1 receptor and the amylin receptor, two gut- and pancreas-derived hormone pathways involved in appetite signaling [1][2]. It has been made in both an injectable and an oral tablet form [1][2][3]. How the two receptor activities combine in humans is still being characterized; published human data so far focus on safety, tolerability, pharmacokinetics and pharmacodynamics [1][2].
| Study | Model | Reported result | Source |
|---|---|---|---|
| Phase 1b/2a injectable trial [2] | Human 125 adults aged 18-55, randomized, placebo-controlled, five parts (single and multiple ascending levels), up to 12 weeks of active study | Measured safety, tolerability, pharmacokinetics and body weight change. Published | Peer-reviewed Lancet 2025 |
| First-in-human oral trial [1] | Human 144 adults, randomized, double-blind, placebo-controlled, multipart, up to 12 weeks | Primary endpoint: adverse events arising during the study. Pharmacokinetics and pharmacodynamics also measured. Published | Peer-reviewed Lancet 2025 |
| Phase 3 program announcement [3] | Human Injectable and oral forms in adults; program design not yet disclosed at announcement | Developer announced phase 3 start planned for the first quarter of 2026 after end-of-phase-2 regulatory interactions | Company-reported Novo Nordisk press release 2025 |
Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.
PureLab does not supply this compound. This page summarizes published research only.
